Skip to main content
SpringerLink
Log in

Tumor Antigen Identification for Cancer Immunotherapy

  • Chapter
  • First Online:
Cancer Immunology

  • 1408 Accesses

Abstract

The immune system has shown to be capable of acting against malignant cells, in which recognizing the tumor antigen is an essential step. Tumor antigens are different in structure, expression and presentation, origin, immunogenicity, etc. Thus, it is very important to identify the antigens with favored properties. Several techniques have been developed for tumor antigen identification; the major two categories are indirect immunology based on algorithms predicting the HLA-peptide binding affinity ranking the candidate antigens which will further be validated versus direct HLA peptidomics approach which derives samples, isolates HLA-peptide complex, and determines the sequence of the peptide as a tumor antigen. Better antitumor immunotherapeutics such as personalized medicine, efficient adoptive T-cell therapy, immune vaccines, etc. will be provided through the development of more advanced antigen identification protocols.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197–216. https://doi.org/10.1146/annurev.immunol.20.083001.084359.

    Article  CAS  PubMed  Google Scholar 

  2. Lu Y-C, Robbins PF. Cancer immunotherapy targeting neoantigens. Semin Immunol. 2016;28(1):22–7. https://doi.org/10.1016/j.smim.2015.11.002.

    Article  CAS  PubMed  Google Scholar 

  3. Meeusen E, Lim E, Mathivanan S. Secreted tumor antigens - immune biomarkers for diagnosis and therapy. Proteomics. 2017;17(23-24) https://doi.org/10.1002/pmic.201600442.

  4. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991–8. https://doi.org/10.1038/ni1102-991.

    Article  CAS  PubMed  Google Scholar 

  5. Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009;114(3):535–46. https://doi.org/10.1182/blood-2009-03-211714.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Cerezo-Wallis D, Soengas MS. Understanding tumor-antigen presentation in the new era of cancer immunotherapy. Curr Pharm Des. 2016;22(41):6234–50. https://doi.org/10.2174/1381612822666160826111041.

    Article  CAS  PubMed  Google Scholar 

  7. Khodadoust MS, Alizadeh AA. Tumor antigen discovery through translation of the cancer genome. Immunol Res. 2014;58(2-3):292–9. https://doi.org/10.1007/s12026-014-8505-4.

    Article  CAS  PubMed  Google Scholar 

  8. Chu Y, Liu Q, Wei J, et al. Personalized cancer neoantigen vaccines come of age. Theranostics. 2018;8(15):4238–46. https://doi.org/10.7150/thno.24387.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Scanlan MJ, Gure AO, Jungbluth AA, et al. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev. 2002;188:22–32. https://doi.org/10.1034/j.1600-065x.2002.18803.x.

    Article  CAS  PubMed  Google Scholar 

  10. van Esch EM, Tummers B, Baartmans V, et al. Alterations in classical and nonclassical HLA expression in recurrent and progressive HPV-induced usual vulvar intraepithelial neoplasia and implications for immunotherapy. Int J Cancer. 2014;135(4):830–42. https://doi.org/10.1002/ijc.28713.

    Article  CAS  PubMed  Google Scholar 

  11. Elgui de Oliveira D, Müller-Coan BG, Pagano JS. Viral carcinogenesis beyond malignant transformation: EBV in the progression of human cancers. Trends Microbiol. 2016;24(8):649–64. https://doi.org/10.1016/j.tim.2016.03.008.

    Article  CAS  PubMed  Google Scholar 

  12. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science (New York, NY). 2015;348(6230):69–74. https://doi.org/10.1126/science.aaa4971.

    Article  CAS  Google Scholar 

  13. Kessler JH, Melief CJ. Identification of T-cell epitopes for cancer immunotherapy. Leukemia. 2007;21(9):1859–74. https://doi.org/10.1038/sj.leu.2404787.

    Article  CAS  PubMed  Google Scholar 

  14. Kuhlmann L, Cummins E, Samudio I, et al. Cell-surface proteomics for the identification of novel therapeutic targets in cancer. Expert Rev Proteomics. 2018;15(3):259–75. https://doi.org/10.1080/14789450.2018.1429924.

    Article  CAS  PubMed  Google Scholar 

  15. Kalaora S, Samuels Y. Cancer exome-based identification of tumor neo-antigens using mass spectrometry. Methods Mol Biol. 2019;1884:203–14. https://doi.org/10.1007/978-1-4939-8885-3_14.

    Article  CAS  PubMed  Google Scholar 

  16. Novellino L, Renkvist N, Rini F, et al. Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen. J Immunol. 2003;170(12):6363–70. https://doi.org/10.4049/jimmunol.170.12.6363.

    Article  CAS  PubMed  Google Scholar 

  17. Echchakir H, Mami-Chouaib F, Vergnon I, et al. A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res. 2001;61(10):4078–83.

    CAS  PubMed  Google Scholar 

  18. Zhou X, Jun DY, Thomas AM, et al. Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine. Cancer Res. 2005;65(3):1079–88.

    CAS  PubMed  Google Scholar 

  19. Sharkey MS, Lizée G, Gonzales MI, et al. CD4(+) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation. Cancer Res. 2004;64(5):1595–9. https://doi.org/10.1158/0008-5472.can-03-3231.

    Article  CAS  PubMed  Google Scholar 

  20. Li Y, Zhang Q, Peng B, et al. Identification of glutathione S-transferase omega 1 (GSTO1) protein as a novel tumor-associated antigen and its autoantibody in human esophageal squamous cell carcinoma. Tumour Biol. 2014;35(11):10871–7. https://doi.org/10.1007/s13277-014-2394-y.

    Article  CAS  PubMed  Google Scholar 

  21. Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science (New York, NY). 2014;344(6184):641–5. https://doi.org/10.1126/science.1251102.

    Article  CAS  Google Scholar 

  22. Nielsen M, Lundegaard C, Blicher T, et al. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS One. 2007;2(8):e796. https://doi.org/10.1371/journal.pone.0000796.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Traversari C, van der Bruggen P, Luescher IF, et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med. 1992;176(5):1453–7. https://doi.org/10.1084/jem.176.5.1453.

    Article  CAS  PubMed  Google Scholar 

  24. Traversari C, van der Bruggen P, Van den Eynde B, et al. Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes. Immunogenetics. 1992;35(3):145–52. https://doi.org/10.1007/bf00185107.

    Article  CAS  PubMed  Google Scholar 

  25. Robbins PF, Lu YC, El-Gamil M, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013;19(6):747–52. https://doi.org/10.1038/nm.3161.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Vuckovic D, Dagley LF, Purcell AW, et al. Membrane proteomics by high performance liquid chromatography-tandem mass spectrometry: analytical approaches and challenges. Proteomics. 2013;13(3-4):404–23. https://doi.org/10.1002/pmic.201200340.

    Article  CAS  PubMed  Google Scholar 

  27. Bassani-Sternberg M, Bräunlein E, Klar R, et al. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat Commun. 2016;7:13404. https://doi.org/10.1038/ncomms13404.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Ott PA, Hu Z, Keskin DB, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217–21. https://doi.org/10.1038/nature22991.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Tran E, Robbins PF, Lu YC, et al. T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med. 2016;375(23):2255–62. https://doi.org/10.1056/NEJMoa1609279.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Heemskerk B, Kvistborg P, Schumacher TN. The cancer antigenome. EMBO J. 2013;32(2):194–203. https://doi.org/10.1038/emboj.2012.333.

    Article  CAS  PubMed  Google Scholar 

  31. McGranahan N, Furness AJ, Rosenthal R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science (New York, NY). 2016;351(6280):1463–9. https://doi.org/10.1126/science.aaf1490.

    Article  CAS  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Center for Immunodeficiencies, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran

    Maryam Balibegloo & Nima Rezaei

  2. Cancer Immunology Project (CIP), Universal Scientific Education & Research Network (USERN), Tehran, Iran

    Maryam Balibegloo & Mahsa Keshavarz-Fathi

  3. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

    Mahsa Keshavarz-Fathi

  4. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

    Nima Rezaei

  5. Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran

    Nima Rezaei

Authors
  1. Maryam Balibegloo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mahsa Keshavarz-Fathi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nima Rezaei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nima Rezaei .

Editor information

Editors and Affiliations

  1. Research Center for Immunodeficiencies, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran

    Nima Rezaei

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Balibegloo, M., Keshavarz-Fathi, M., Rezaei, N. (2021). Tumor Antigen Identification for Cancer Immunotherapy. In: Rezaei, N. (eds) Cancer Immunology. Springer, Cham. https://doi.org/10.1007/978-3-030-50287-4_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-50287-4_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-50286-7

  • Online ISBN: 978-3-030-50287-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation